GIVEN DOUGLAS B
Known title: DirectorCIK: 0001156207
GIVEN DOUGLAS B's purchase track record
GIVEN DOUGLAS B has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/28/2021 | ARWR | $43K | -29.3% | -50.8% | -20.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ARWR | ▼ Sell | Open Market | 547 | $12K | 12/17/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 5,000 | $110K | 12/16/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,100 | $42K | 1/11/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,811 | $68K | 1/11/2024 | View on chart |
| ARWR | ▲ Buy | Grant | 14,987 | $381K | 12/15/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 6,500 | $266K | 5/5/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 875 | $29K | 2/27/2023 | View on chart |
| ARWR | ▲ Buy | Grant | 7,867 | $0 | 1/10/2023 | View on chart |
| ARWR | ▲ Buy | Grant | 6,400 | $0 | 1/7/2022 | View on chart |
| ARWR | ▼ Sell | Gift | 655 | $0 | 12/28/2021 | View on chart |
| ARWR | ▲ Buy | Open Market | 655 | $43K | 12/28/2021 | View on chart |
| ARWR | ▼ Sell | Open Market | 5,000 | $326K | 9/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value
Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value. Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.